NL
DE
As a UMC/University we are experts in finding biomolecular processes that are the cause of diseases. This can result in the discovery of new targets for therapeutic purposes. To find and further develop the therapeutics that can manipulate these targets, we need external partners. Therefore, we partnered with the Centre for Drug Design and Discovery (CD3), an organization that arised from the University of Leuven. As a researcher you now have the chance to turn your target into a therapeutic! The nice thing about our collaboration is that CD3 brings knowledge and cash on the table to develop a novel therapeutic agent while we both benefit from the possible commercial outcome. More information about CD3 can be found below in Italic and on their website.
If you are a researcher and you think you have an interesting (druggable) target please contact rick.meurders@radboudumc.nl. The next step is an introduction with CD3 to explore the possibilities. Thanks!
CD3 is a drug discovery centre and investment fund (84 mill. €) created to facilitate the translation of innovative basic research to the clinic. Their model is based on hand-in-hand collaborations with academic research groups aimed at developing new drugs, whether being small molecule or antibody-based drugs. The experienced drug discovery team invests in very early drug discovery projects and complements academic research groups with industry-standard drug discovery capabilities (assay development, high-throughput screening, in silico modelling, antibody discovery, medicinal chemistry, ADME-Tox/PK, IP support). Successful collaborations lead to licensing agreements with pharma or biotech companies and/or the creation of spin-off companies. CD3 has a track record of successful drug discovery collaborations with academic research groups, exemplified by the out-licensing of drug candidates to pharma companies such as Pfizer, AstraZeneca, Novartis and Janssen and the creation of several spin-off companies like Rewind Therapeutics and Cytura Therapeutics.
